House Reform Bill's Part D Changes Would Boost Premiums 20% By 2019, CBO Says
This article was originally published in The Pink Sheet Daily
However, the cost to beneficiaries of increased premiums would be offset, on average, by the lower cost-sharing that would result from the legislation, CBO adds.
You may also be interested in...
The Congressional Budget Office has put a value on the net savings that would accrue to the federal government through drug rebate and discount provisions in the pending House health care reform bill: $48 billion over 10 years
The House health care reform bill contains a number of provisions that would greatly expand the market for pharmaceuticals, but the bill seeks a number of financial concessions from pharmaceutical manufacturers, prompting a statement of protest from the industry association
Investigative reports from the House Oversight and Reform Committee recount well-known records of significant price increases for the drugs, the lack of pricing restraints in the US relative to markets abroad, tactics used to protect the drugs from generic competition and the 'return on investment' from manufacturer assistance programs.